Brief: Monopar Announces Encouraging Clinical Data From Ongoing Camsirubicin Phase 1B Trial
16/11/2022 12:03
Nov 16 (Reuters) - Monopar Therapeutics Inc MNPR.O :
* MONOPAR ANNOUNCES ENCOURAGING CLINICAL DATA FROM ONGOING
CAMSIRUBICIN PHASE 1B TRIAL
* MONOPAR ANNOUNCES ENCOURAGING CLINICAL DATA FROM ONGOING
CAMSIRUBICIN PHASE 1B TRIAL
* MONOPAR THERAPEUTICS INC - NO DRUG-RELATED CLINICAL
CARDIOTOXICITY HAS BEEN OBSERVED IN ANY PATIENT
* MONOPAR THERAPEUTICS INC - TRIAL IS CONTINUING TO ENROLL
AND
DOSE-ESCALATE, AS THERE HAVE BEEN NO SIGNS OF HAVING YET HIT
MAXIMUM TOLERATED DOSE
Source text for Eikon: ID:nGNX2QZdy9
Further company coverage: MNPR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Monopar Therapeutics
See all newsBrief: Monopar Appoints Jeffrey D. Kent, M.D., As Executive Vice President, Head Of Medical Affairs Announces Two Alxn1840 Presentations At Aasld – The Liver Meeting 2026
U.S. RESEARCH ROUNDUP-Airbnb, Five Below, Silgan Holdings
Monopar Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Monopar Therapeutics Inc. expected to post a loss of 62 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Alphabet, IBM, Tesla